Vascepa – which will be sold as Vazkepa in Europe – reduces harmful blood fats called triglycerides in patients at risk of potentially fatal heart attack or stroke.

Amarin, the Irish biotech that developed a cardiovascular drug out of refined fish oil, is gearing up for a launch in Europe. It will be a further va(...)

Shares in cardiovascular drugmaker Amarin slumped over 70% last night as the company lost a key patent case in Nevada.

Shares in Irish heart drug company Amarin slumped more than 70 per cent last night as the company lost a key court case in Nevada over the patents of (...)

Irish drug company Amarin says sales from Vascepa, its one cardiovascular drug for 2019, will be at or above the upper end of its previous guidance

Irish drug company Amarin says sales from its one cardiovascular drug for 2019 will be at or above the upper end of its previous guidance – indicating(...)